<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE chapter PUBLIC "-//ES//DTD book DTD version 5.5.0//EN//XML" "book550.dtd" [<!ENTITY f026-001-9780702070280 SYSTEM "f026-001-9780702070280" NDATA IMAGE><!ENTITY f026-002-9780702070280 SYSTEM "f026-002-9780702070280" NDATA IMAGE><!ENTITY f026-003-9780702070280 SYSTEM "f026-003-9780702070280" NDATA IMAGE><!ENTITY f026-004-9780702070280 SYSTEM "f026-004-9780702070280" NDATA IMAGE><!ENTITY f026-005-9780702070280 SYSTEM "f026-005-9780702070280" NDATA IMAGE><!ENTITY f026-006-9780702070280 SYSTEM "f026-006-9780702070280" NDATA IMAGE><!ENTITY f026-007-9780702070280 SYSTEM "f026-007-9780702070280" NDATA IMAGE><!ENTITY f026-008-9780702070280 SYSTEM "f026-008-9780702070280" NDATA IMAGE><!ENTITY f026-009-9780702070280 SYSTEM "f026-009-9780702070280" NDATA IMAGE><!ENTITY f026-010-9780702070280 SYSTEM "f026-010-9780702070280" NDATA IMAGE><!ENTITY f026-011-9780702070280 SYSTEM "f026-011-9780702070280" NDATA IMAGE><!ENTITY f026-012-9780702070280 SYSTEM "f026-012-9780702070280" NDATA IMAGE><!ENTITY f026-013-9780702070280 SYSTEM "f026-013-9780702070280" NDATA IMAGE><!ENTITY f026-014-9780702070280 SYSTEM "f026-014-9780702070280" NDATA IMAGE><!ENTITY icon01-9780702070280 SYSTEM "icon01-9780702070280" NDATA IMAGE><!ENTITY icon02-9780702070280 SYSTEM "icon02-9780702070280" NDATA IMAGE><!ENTITY icon03-9780702070280 SYSTEM "icon03-9780702070280" NDATA IMAGE><!ENTITY icon06-9780702070280 SYSTEM "icon06-9780702070280" NDATA IMAGE><!ENTITY u026-001-9780702070280 SYSTEM "u026-001-9780702070280" NDATA IMAGE><!ENTITY u026-002-9780702070280 SYSTEM "u026-002-9780702070280" NDATA IMAGE>]><chapter docsubtype="chp" id="c00026" version="5.5" xml:lang="en" xmlns="http://www.elsevier.com/xml/bk/dtd" xmlns:ce="http://www.elsevier.com/xml/common/dtd" xmlns:xlink="http://www.w3.org/1999/xlink"><info><ce:pii>B978-0-7020-7028-0.00026-3</ce:pii><ce:doi>10.1016/B978-0-7020-7028-0.00026-3</ce:doi><ce:isbn>978-0-7020-7028-0</ce:isbn><ce:copyright type="full-transfer" year="2018">Elsevier Ltd</ce:copyright></info><ce:floats><ce:figure id="f0020"><ce:label>Fig. 26.1</ce:label><ce:caption id="ca0015"><ce:simple-para id="sp0020" role="title">A classification of stroke disease.</ce:simple-para></ce:caption><ce:alt-text id="atte0010" role="short">Fig. 26.1</ce:alt-text><ce:link id="ln0020" locator="f026-001-9780702070280" xlink:href="pii:B9780702070280000263/f026-001-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0025"><ce:label>Fig. 26.2</ce:label><ce:caption id="ca0020"><ce:simple-para id="sp0025" role="title">Arterial circulation of the brain.</ce:simple-para><ce:simple-para id="sp0030" role="caption"><ce:bold>A</ce:bold> Horizontal view. <ce:bold>B</ce:bold> Lateral view.</ce:simple-para></ce:caption><ce:alt-text id="atte0015" role="short">Fig. 26.2</ce:alt-text><ce:link id="ln0025" locator="f026-002-9780702070280" xlink:href="pii:B9780702070280000263/f026-002-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0030"><ce:label>Fig. 26.3</ce:label><ce:caption id="ca0025"><ce:simple-para id="sp0035" role="title">Venous circulation of the brain.</ce:simple-para></ce:caption><ce:alt-text id="atte0020" role="short">Fig. 26.3</ce:alt-text><ce:link id="ln0030" locator="f026-003-9780702070280" xlink:href="pii:B9780702070280000263/f026-003-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0035"><ce:label>Fig. 26.4</ce:label><ce:caption id="ca0030"><ce:simple-para id="sp0040" role="title">Acute stroke seen on computed tomography (CT) scan with corresponding magnetic resonance imaging (MRI) appearance.</ce:simple-para><ce:simple-para id="sp0045" role="caption"><ce:bold>A</ce:bold> CT may show no evidence of early infarction. <ce:bold>B</ce:bold> A corresponding image seen on MRI diffusion weighted imaging (DWI) with changes of infarction in the middle cerebral artery (MCA) territory (arrows).</ce:simple-para></ce:caption><ce:alt-text id="atte0025" role="short">Fig. 26.4</ce:alt-text><ce:source>A and B, Courtesy of Dr A. Farrell and Prof. J. Wardlaw.</ce:source><ce:link id="ln0035" locator="f026-004-9780702070280" xlink:href="pii:B9780702070280000263/f026-004-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0040"><ce:label>Fig. 26.5</ce:label><ce:caption id="ca0035"><ce:simple-para id="sp0050" role="title">Different techniques for imaging blood vessels.</ce:simple-para><ce:simple-para id="sp0055" role="caption"><ce:bold>A</ce:bold> Doppler scan showing 80% stenosis of the internal carotid artery (arrow). <ce:bold>B</ce:bold> Three-dimensional reconstruction of CT angiogram showing stenosis at the carotid bifurcation (arrow). <ce:bold>C</ce:bold> MR angiogram showing giant aneurysm at the middle cerebral artery bifurcation (arrow). <ce:bold>D</ce:bold> Intra-arterial angiography showing arteriovenous malformation (arrow).</ce:simple-para></ce:caption><ce:alt-text id="atte0030" role="short">Fig. 26.5</ce:alt-text><ce:source>A–D, Courtesy of Dr D. Collie.</ce:source><ce:link id="ln0040" locator="f026-005-9780702070280" xlink:href="pii:B9780702070280000263/f026-005-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0045"><ce:label>Fig. 26.6</ce:label><ce:caption id="ca0040"><ce:simple-para id="sp0060" role="title">Homeostatic responses to falling perfusion pressure in the brain following arterial occlusion.</ce:simple-para><ce:simple-para id="sp0065" role="caption">Vasodilatation initially maintains cerebral blood flow (A), but after maximal vasodilatation further falls in perfusion pressure lead to a decline in blood flow. An increase in tissue oxygen extraction, however, maintains the cerebral metabolic rate for oxygen (B). Still further falls in perfusion, and therefore blood flow, cannot be compensated; cerebral oxygen availability falls and symptoms appear, then infarction (C).</ce:simple-para></ce:caption><ce:alt-text id="atte0035" role="short">Fig. 26.6</ce:alt-text><ce:link id="ln0050" locator="f026-006-9780702070280" xlink:href="pii:B9780702070280000263/f026-006-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0050"><ce:label>Fig. 26.7</ce:label><ce:caption id="ca0045"><ce:simple-para id="sp0070" role="title">Thresholds of cerebral ischaemia.</ce:simple-para><ce:simple-para id="sp0075" role="caption">Symptoms of cerebral ischaemia appear when the blood flow has fallen to less than half of normal and energy supply is insufficient to sustain neuronal electrical function. Full recovery can occur if this level of flow is returned to normal but not if it is sustained. Further blood flow reduction below the next threshold causes failure of cell ionic pumps and starts the ischaemic cascade, leading to cell death.</ce:simple-para></ce:caption><ce:alt-text id="atte0040" role="short">Fig. 26.7</ce:alt-text><ce:link id="ln0055" locator="f026-007-9780702070280" xlink:href="pii:B9780702070280000263/f026-007-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0055"><ce:label>Fig. 26.8</ce:label><ce:caption id="ca0050"><ce:simple-para id="sp0080" role="title">The process of neuronal ischaemia and infarction.</ce:simple-para><ce:simple-para id="sp0085" role="caption">(1) Reduction of blood flow reduces supply of oxygen and hence adenosine triphosphate (ATP). H<ce:sup loc="post">+</ce:sup> is produced by anaerobic metabolism of available glucose. (2) Energy-dependent membrane ionic pumps fail, leading to cytotoxic oedema and membrane depolarisation, allowing calcium entry and releasing glutamate. (3) Calcium enters cells via glutamate-gated channels and (4) activates destructive intracellular enzymes (5), destroying intracellular organelles and cell membrane, with release of free radicals. Free fatty acid release activates pro-coagulant pathways that exacerbate local ischaemia. (6) Glial cells take up H<ce:sup loc="post">+</ce:sup>, can no longer take up extracellular glutamate and also suffer cell death, leading to liquefactive necrosis of whole arterial territory. (AMPA = α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; NMDA = <ce:italic>N</ce:italic>-methyl-<ce:small-caps>d</ce:small-caps>-aspartate; NO = nitric oxide)</ce:simple-para></ce:caption><ce:alt-text id="atte0045" role="short">Fig. 26.8</ce:alt-text><ce:link id="ln0060" locator="f026-008-9780702070280" xlink:href="pii:B9780702070280000263/f026-008-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0060"><ce:label>Fig. 26.9</ce:label><ce:caption id="ca0055"><ce:simple-para id="sp0090" role="title">CT scans showing intracerebral haemorrhage.</ce:simple-para><ce:simple-para id="sp0095" role="caption"><ce:bold>A</ce:bold> Basal ganglia haemorrhage with intraventricular extension. <ce:bold>B</ce:bold> Small cortical haemorrhage.</ce:simple-para></ce:caption><ce:alt-text id="atte0050" role="short">Fig. 26.9</ce:alt-text><ce:source>A and B, Courtesy of Dr A. Farrell and Prof. J. Wardlaw.</ce:source><ce:link id="ln0065" locator="f026-009-9780702070280" xlink:href="pii:B9780702070280000263/f026-009-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0065"><ce:label>Fig. 26.10</ce:label><ce:caption id="ca0060"><ce:simple-para id="sp0100" role="title">Clinical and radiological features of the stroke syndromes.</ce:simple-para><ce:simple-para id="sp0105" role="caption">The top three diagrams show coronal sections of the brain and the bottom one shows a sagittal section. The anatomical locations of cerebral functions are shown with the nerve tracts in green. A motor (or sensory) deficit (shown by the areas shaded red) can occur with damage to the relevant cortex (PACS), nerve tracts (LACS) or both (TACS). The corresponding CT scans show horizontal slices at the level of the lesion, highlighted by the arrows.</ce:simple-para></ce:caption><ce:alt-text id="atte0055" role="short">Fig. 26.10</ce:alt-text><ce:link id="ln0085" locator="f026-010-9780702070280" xlink:href="pii:B9780702070280000263/f026-010-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0070"><ce:label>Fig. 26.11</ce:label><ce:caption id="ca0065"><ce:simple-para id="sp0120" role="title">Emergency management of stroke.</ce:simple-para><ce:simple-para id="sp0125" role="caption">*Varies with patient selection and delay in treatment. (NNT = number needed to treat to avoid one death or long-term disability)</ce:simple-para></ce:caption><ce:alt-text id="atte0060" role="short">Fig. 26.11</ce:alt-text><ce:link id="ln0105" locator="f026-011-9780702070280" xlink:href="pii:B9780702070280000263/f026-011-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0075"><ce:label>Fig. 26.12</ce:label><ce:caption id="ca0070"><ce:simple-para id="sp0130" role="title">Complications of acute stroke.</ce:simple-para></ce:caption><ce:alt-text id="atte0065" role="short">Fig. 26.12</ce:alt-text><ce:link id="ln0110" locator="f026-012-9780702070280" xlink:href="pii:B9780702070280000263/f026-012-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0080"><ce:label>Fig. 26.13</ce:label><ce:caption id="ca0075"><ce:simple-para id="sp0135" role="title">Strategies for secondary prevention of stroke.</ce:simple-para><ce:simple-para id="sp0140" role="caption">(1) Lower blood pressure with caution in patients with postural hypotension, renal impairment or bilateral carotid stenosis. (2) Other statins can be used as an alternative to simvastatin in patients on warfarin or digoxin. (3) Warfarin and aspirin have been used in combination in patients with prosthetic heart valves. (4) The combination of aspirin and clopidogrel is indicated only in patients with unstable angina or those with a temporary high risk of recurrence (e.g. carotid stenosis). (ACE = angiotensin-converting enzyme; BP = blood pressure; CT = computed tomography; ECG = electrocardiogram; MRI = magnetic resonance imaging; TIA = transient ischaemic attack; U&#x0026;Es = urea and electrolytes)</ce:simple-para></ce:caption><ce:alt-text id="atte0070" role="short">Fig. 26.13</ce:alt-text><ce:link id="ln0125" locator="f026-013-9780702070280" xlink:href="pii:B9780702070280000263/f026-013-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0085"><ce:label>Fig. 26.14</ce:label><ce:caption id="ca0080"><ce:simple-para id="sp0145" role="title">Investigation of subarachnoid haemorrhage.</ce:simple-para><ce:simple-para id="sp9000" role="caption">(CSF = cerebrospinal fluid; CT = computed tomography)</ce:simple-para></ce:caption><ce:alt-text id="atte0075" role="short">Fig. 26.14</ce:alt-text><ce:link id="ln0130" locator="f026-014-9780702070280" xlink:href="pii:B9780702070280000263/f026-014-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:textbox id="b0020" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0045" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000263/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0080" role="short">Image 1</ce:alt-text></ce:inline-figure>26.1</ce:label><ce:alt-text id="atte0085" role="short">26.1</ce:alt-text><ce:textbox-head><ce:title id="tit0025">Risk factors for stroke</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p0450"><ce:display><ce:table frame="topbot" id="t0015"><ce:alt-text id="atte0090" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Fixed risk factors</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0090"><ce:list-item id="u0280"><ce:label>•</ce:label><ce:para id="p0455">Age</ce:para></ce:list-item><ce:list-item id="u0285"><ce:label>•</ce:label><ce:para id="p0460">Gender (male &#x003E; female except at extremes of age)</ce:para></ce:list-item><ce:list-item id="u0290"><ce:label>•</ce:label><ce:para id="p0465">Race (Afro-Caribbean &#x003E; Asian &#x003E; European)</ce:para></ce:list-item><ce:list-item id="u0295"><ce:label>•</ce:label><ce:para id="p0470">Previous vascular event:<ce:list id="ulist0095"><ce:list-item id="u0300"><ce:para id="p0475">Myocardial infarction</ce:para></ce:list-item><ce:list-item id="u0305"><ce:para id="p0480">Stroke</ce:para></ce:list-item><ce:list-item id="u0310"><ce:para id="p0485">Peripheral vascular disease</ce:para></ce:list-item></ce:list></ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="olist9000"><ce:list-item id="u0315"><ce:label>•</ce:label><ce:para id="p0490">Heredity</ce:para></ce:list-item><ce:list-item id="u0320"><ce:label>•</ce:label><ce:para id="p0495">Sickle cell disease</ce:para></ce:list-item><ce:list-item id="u0325"><ce:label>•</ce:label><ce:para id="p0500">High fibrinogen</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Modifiable risk factors</ce:bold></entry></row><row><entry align="left"><ce:list id="ulist0100"><ce:list-item id="u0330"><ce:label>•</ce:label><ce:para id="p0505">Blood pressure</ce:para></ce:list-item><ce:list-item id="u0335"><ce:label>•</ce:label><ce:para id="p0510">Cigarette smoking</ce:para></ce:list-item><ce:list-item id="u0340"><ce:label>•</ce:label><ce:para id="p0515">Hyperlipidaemia</ce:para></ce:list-item><ce:list-item id="u0345"><ce:label>•</ce:label><ce:para id="p0520">Diabetes mellitus</ce:para></ce:list-item><ce:list-item id="u0350"><ce:label>•</ce:label><ce:para id="p0525">Heart disease:<ce:list id="ulist0105"><ce:list-item id="u0355"><ce:para id="p0530">Atrial fibrillation</ce:para></ce:list-item><ce:list-item id="u0360"><ce:para id="p0535">Congestive cardiac failure</ce:para></ce:list-item><ce:list-item id="u0365"><ce:para id="p0540">Infective endocarditis</ce:para></ce:list-item></ce:list></ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0110"><ce:list-item id="u0370"><ce:label>•</ce:label><ce:para id="p0545">Excessive alcohol intake</ce:para></ce:list-item><ce:list-item id="u0375"><ce:label>•</ce:label><ce:para id="p0550">Oestrogen-containing drugs:<ce:list id="ulist0115"><ce:list-item id="u0380"><ce:para id="p0555">Oral contraceptive pill</ce:para></ce:list-item><ce:list-item id="u0385"><ce:para id="p0560">Hormone replacement therapy</ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u0390"><ce:label>•</ce:label><ce:para id="p0565">Polycythaemia</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0025" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0070" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000263/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0095" role="short">Image 2</ce:alt-text></ce:inline-figure>26.2</ce:label><ce:alt-text id="atte0100" role="short">26.2</ce:alt-text><ce:textbox-head><ce:title id="tit0030">Causes of intracerebral haemorrhage and associated risk factors</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p0590"><ce:display><ce:table frame="topbot" id="t0020"><ce:alt-text id="atte0105" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><thead><row rowsep="1"><entry align="left">Disease</entry><entry align="left">Risk factors</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Complex small-vessel disease with disruption of vessel wall</ce:bold></entry><entry align="left">Age<ce:br/>Hypertension<ce:br/>High cholesterol</entry></row><row rowsep="1"><entry align="left"><ce:bold>Amyloid angiopathy</ce:bold></entry><entry align="left">Familial (rare)<ce:br/>Age</entry></row><row rowsep="1"><entry align="left"><ce:bold>Impaired blood clotting</ce:bold></entry><entry align="left">Anticoagulant therapy<ce:br/>Blood dyscrasia<ce:br/>Thrombolytic therapy</entry></row><row rowsep="1"><entry align="left"><ce:bold>Vascular anomaly</ce:bold></entry><entry align="left">Arteriovenous malformation<ce:br/>Cavernous haemangioma</entry></row><row><entry align="left"><ce:bold>Substance misuse</ce:bold></entry><entry align="left">Alcohol<ce:br/>Amphetamines<ce:br/>Cocaine</entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0030" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0075" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000263/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0110" role="short">Image 3</ce:alt-text></ce:inline-figure>26.3</ce:label><ce:alt-text id="atte0115" role="short">26.3</ce:alt-text><ce:textbox-head><ce:title id="tit0035">Differential diagnosis of stroke and transient ischaemic attack</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p0600"><ce:display><ce:table frame="topbot" id="t0025"><ce:alt-text id="atte0120" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>‘Structural’ stroke mimics</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0120"><ce:list-item id="u0395"><ce:label>•</ce:label><ce:para id="p0605">Primary cerebral tumours</ce:para></ce:list-item><ce:list-item id="u0400"><ce:label>•</ce:label><ce:para id="p0610">Metastatic cerebral tumours</ce:para></ce:list-item><ce:list-item id="u0405"><ce:label>•</ce:label><ce:para id="p0615">Extradural or subdural haematoma</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0125"><ce:list-item id="u0420"><ce:label>•</ce:label><ce:para id="p0630">Demyelination</ce:para></ce:list-item><ce:list-item id="u0415"><ce:label>•</ce:label><ce:para id="p0625">Peripheral nerve lesions (vascular or compressive)</ce:para></ce:list-item><ce:list-item id="u0410"><ce:label>•</ce:label><ce:para id="p0620">Cerebral abscess</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>‘Functional’ stroke mimics</ce:bold></entry></row><row><entry align="left"><ce:list id="ulist0130"><ce:list-item id="u0425"><ce:label>•</ce:label><ce:para id="p0635">Todd's paresis (after epileptic seizure)</ce:para></ce:list-item><ce:list-item id="u0430"><ce:label>•</ce:label><ce:para id="p0640">Hypoglycaemia</ce:para></ce:list-item><ce:list-item id="u0435"><ce:label>•</ce:label><ce:para id="p0645">Migrainous aura (with or without headache)</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0135"><ce:list-item id="u0440"><ce:label>•</ce:label><ce:para id="p0650">Focal seizures</ce:para></ce:list-item><ce:list-item id="u0445"><ce:label>•</ce:label><ce:para id="p0655">Ménière's disease or other vestibular disorder</ce:para></ce:list-item><ce:list-item id="u0450"><ce:label>•</ce:label><ce:para id="p0660">Conversion disorder (<ce:intra-ref id="ii0140" xlink:href="pii:B978-0-7020-7028-0.00028-7#s1025">p. 1202</ce:intra-ref>)</ce:para></ce:list-item><ce:list-item id="u0455"><ce:label>•</ce:label><ce:para id="p0665">Encephalitis</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0035" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0080" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000263/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0125" role="short">Image 4</ce:alt-text></ce:inline-figure>26.4</ce:label><ce:alt-text id="atte0130" role="short">26.4</ce:alt-text><ce:textbox-head><ce:title id="tit0040">Characteristic features of stroke and non-stroke syndromes (‘stroke mimics’)</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p0670"><ce:display><ce:table frame="topbot" id="t0030"><ce:alt-text id="atte0135" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left">Feature</entry><entry align="left">Stroke</entry><entry align="left">Stroke mimics</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Symptom onset</ce:bold></entry><entry align="left">Sudden (minutes)</entry><entry align="left">Often slower onset</entry></row><row rowsep="1"><entry align="left"><ce:bold>Symptom progression</ce:bold></entry><entry align="left">Rapidly reaches maximum severity</entry><entry align="left">Often gradual onset</entry></row><row rowsep="1"><entry align="left"><ce:bold>Severity of deficit</ce:bold></entry><entry align="left">Unequivocal</entry><entry align="left">May be variable/uncertain</entry></row><row rowsep="1"><entry align="left"><ce:bold>Pattern of deficit</ce:bold></entry><entry align="left">Hemispheric pattern</entry><entry align="left">May be non-specific with delirium, memory loss, balance disturbance</entry></row><row><entry align="left"><ce:bold>Loss of consciousness</ce:bold></entry><entry align="left">Uncommon</entry><entry align="left">More common</entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0040" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0090" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000263/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0140" role="short">Image 5</ce:alt-text></ce:inline-figure>26.5</ce:label><ce:alt-text id="atte0145" role="short">26.5</ce:alt-text><ce:textbox-head><ce:title id="tit0045">Investigation of a patient with an acute stroke</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p0725"><ce:display><ce:table frame="topbot" id="t0035"><ce:alt-text id="atte0150" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><thead><row rowsep="1"><entry align="left">Diagnostic question</entry><entry align="left">Investigation</entry></row></thead><tbody><row rowsep="1"><entry align="left">Is it a vascular lesion?</entry><entry align="left">CT/MRI</entry></row><row rowsep="1"><entry align="left">Is it ischaemic or haemorrhagic?</entry><entry align="left">CT/MRI</entry></row><row rowsep="1"><entry align="left">Is it a subarachnoid haemorrhage?</entry><entry align="left">CT/lumbar puncture</entry></row><row><entry morerows="2" rowsep="1" align="left">Is there any cardiac source of embolism?</entry><entry rowsep="0" align="left">ECG</entry></row><row rowsep="0"><entry align="left">Holter monitoring</entry></row><row rowsep="1"><entry align="left">Echocardiogram</entry></row><row><entry morerows="3" rowsep="1" align="left">What is the underlying vascular disease?</entry><entry rowsep="0" align="left">Duplex ultrasound of carotids</entry></row><row rowsep="0"><entry align="left">MRA</entry></row><row rowsep="0"><entry align="left">CTA</entry></row><row rowsep="1"><entry align="left">Contrast angiography</entry></row><row><entry morerows="2" rowsep="1" align="left">What are the risk factors?</entry><entry rowsep="0" align="left">Full blood count</entry></row><row rowsep="0"><entry align="left">Cholesterol</entry></row><row rowsep="1"><entry align="left">Blood glucose</entry></row><row><entry morerows="2" align="left">Is there an unusual cause?</entry><entry rowsep="0" align="left">ESR</entry></row><row rowsep="0"><entry align="left">Serum protein electrophoresis</entry></row><row><entry align="left">Clotting/thrombophilia screen</entry></row></tbody></tgroup><ce:legend><ce:simple-para id="sp0110">(CT = computed tomography; CTA = computed tomographic angiography; ECG = electrocardiogram; ESR = erythrocyte sedimentation rate; MRA = magnetic resonance angiography; MRI = magnetic resonance imaging)</ce:simple-para></ce:legend></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0045" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0095" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000263/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0155" role="short">Image 6</ce:alt-text></ce:inline-figure>26.6</ce:label><ce:alt-text id="atte0160" role="short">26.6</ce:alt-text><ce:textbox-head><ce:title id="tit0050">Causes and investigation of acute stroke in young patients</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p0735"><ce:display><ce:table frame="topbot" id="t0040"><ce:alt-text id="atte0165" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><thead><row rowsep="1"><entry align="left">Cause</entry><entry align="left">Investigation</entry></row></thead><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Cerebral infarct</ce:bold></entry></row><row rowsep="0"><entry align="left">Cardiac embolism</entry><entry align="left">Echocardiography (including transoesophageal)</entry></row><row rowsep="0"><entry align="left">Premature atherosclerosis</entry><entry align="left">Serum lipids</entry></row><row rowsep="0"><entry align="left">Arterial dissection</entry><entry align="left">MRI<ce:br/>CTA</entry></row><row rowsep="0"><entry align="left">Reversible cerebral vasoconstriction syndromes</entry><entry align="left">MRI<ce:br/>CTA</entry></row><row rowsep="0"><entry align="left">Thrombophilia</entry><entry align="left">Protein C, protein S<ce:br/>Antithrombin III<ce:br/>Factor V Leiden, prothrombin</entry></row><row rowsep="0"><entry align="left">Homocystinuria (<ce:intra-ref id="ii0155" xlink:href="pii:B978-0-7020-7028-0.00014-7#p2730">p. 369</ce:intra-ref>)</entry><entry align="left">Urinary amino acids<ce:br/>Methionine loading test</entry></row><row rowsep="0"><entry align="left">Antiphospholipid antibody syndrome (<ce:intra-ref id="ii0160" xlink:href="pii:B978-0-7020-7028-0.00023-8#s1775">p. 977</ce:intra-ref>)</entry><entry align="left">Anticardiolipin antibodies/lupus anticoagulant</entry></row><row rowsep="0"><entry align="left">Systemic lupus erythematosus</entry><entry align="left">ANA</entry></row><row rowsep="0"><entry align="left">Vasculitis (e.g. primary angiitis of the central nervous system)</entry><entry align="left">ESR<ce:br/>CRP<ce:br/>ANCA</entry></row><row rowsep="0"><entry align="left">CADASIL<ce:br/>CARASIL</entry><entry align="left">MRI brain<ce:br/>Genetic analysis<ce:br/>Skin biopsy</entry></row><row rowsep="0"><entry align="left">Mitochondrial cytopathy</entry><entry align="left">Serum lactate<ce:br/>White cell mitochondrial DNA<ce:br/>Muscle biopsy<ce:br/>Mitochondrial molecular genetics</entry></row><row rowsep="0"><entry align="left">Fabry's disease</entry><entry align="left">Alpha-galactosidase levels</entry></row><row rowsep="0"><entry align="left">Sickle cell disease</entry><entry align="left">Sickle cell studies</entry></row><row rowsep="1"><entry align="left">Neurovascular syphilis</entry><entry align="left">Syphilis serology</entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Primary intracerebral haemorrhage</ce:bold></entry></row><row rowsep="0"><entry align="left">AVM</entry><entry align="left">MRI/MRA</entry></row><row rowsep="0"><entry align="left">Drug misuse</entry><entry align="left">Drug screen (amphetamine, cocaine)</entry></row><row rowsep="1"><entry align="left">Coagulopathy</entry><entry align="left">PT and APTT<ce:br/>Platelet count</entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Subarachnoid haemorrhage</ce:bold></entry></row><row rowsep="0"><entry align="left">Saccular (‘berry’) aneurysm</entry><entry align="left">MRI/MRA</entry></row><row rowsep="0"><entry align="left">AVM</entry><entry align="left">MRI/MRA</entry></row><row><entry align="left">Vertebral dissection</entry><entry align="left">MRI/MRA</entry></row></tbody></tgroup><ce:legend><ce:simple-para id="sp0115">(ANA = antinuclear antibody; ANCA = antineutrophil cytoplasmic antibody; APTT = activated partial thromboplastin time; AVM = arteriovenous malformation; CADASIL/CARASIL = cerebral autosomal dominant/recessive arteriopathy with subcortical infarcts and leucoencephalopathy; CRP = C-reactive protein; CTA = computed tomographic angiography; ESR = erythrocyte sedimentation rate; MRA = magnetic resonance angiography; MRI = magnetic resonance imaging; PT = prothrombin time)</ce:simple-para></ce:legend></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0050" role="alt6"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0100" locator="icon06-9780702070280" xlink:href="pii:B9780702070280000263/icon06-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0170" role="short">Image 7</ce:alt-text></ce:inline-figure>26.7</ce:label><ce:alt-text id="atte0175" role="short">26.7</ce:alt-text><ce:textbox-head><ce:title id="tit0055">Indications for immediate CT/MRI in acute stroke</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p0745"><ce:list id="ulist0145"><ce:list-item id="u0480"><ce:label>•</ce:label><ce:para id="p0750">Patient on anticoagulants or with abnormal coagulation</ce:para></ce:list-item><ce:list-item id="u0485"><ce:label>•</ce:label><ce:para id="p0755">Consideration for reperfusion (thrombolysis) or immediate anticoagulation</ce:para></ce:list-item><ce:list-item id="u0490"><ce:label>•</ce:label><ce:para id="p0760">Deteriorating conscious level or rapidly progressing deficits</ce:para></ce:list-item><ce:list-item id="u0495"><ce:label>•</ce:label><ce:para id="p0765">Suspected cerebellar haematoma, to exclude hydrocephalus</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0055" role="alt3"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0115" locator="icon03-9780702070280" xlink:href="pii:B9780702070280000263/icon03-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0180" role="short">Image 8</ce:alt-text></ce:inline-figure>26.8</ce:label><ce:alt-text id="atte0185" role="short">26.8</ce:alt-text><ce:textbox-head><ce:title id="tit0060">How to manage a patient with acute stroke</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s0220"><ce:section-title id="st0215">Airway</ce:section-title><ce:para id="p0795"><ce:list id="ulist0150"><ce:list-item id="u0500"><ce:label>•</ce:label><ce:para id="p0800">Perform bedside screen and keep patient nil by mouth if swallowing unsafe or aspiration occurs</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0225"><ce:section-title id="st0220">Breathing</ce:section-title><ce:para id="p0805"><ce:list id="ulist0155"><ce:list-item id="u0505"><ce:label>•</ce:label><ce:para id="p0810">Check respiratory rate and give oxygen if saturation &#x003C; 95%</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0230"><ce:section-title id="st0225">Circulation</ce:section-title><ce:para id="p0815"><ce:list id="ulist0160"><ce:list-item id="u0510"><ce:label>•</ce:label><ce:para id="p0820">Check peripheral perfusion, pulse and blood pressure, and treat abnormalities with fluid replacement, anti-arrhythmics and inotropic drugs as appropriate</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0235"><ce:section-title id="st0230">Hydration</ce:section-title><ce:para id="p0825"><ce:list id="ulist0165"><ce:list-item id="u0515"><ce:label>•</ce:label><ce:para id="p0830">If signs of dehydration, give fluids parenterally or by nasogastric tube</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0240"><ce:section-title id="st0235">Nutrition</ce:section-title><ce:para id="p0835"><ce:list id="ulist0170"><ce:list-item id="u0520"><ce:label>•</ce:label><ce:para id="p0840">Assess nutritional status and provide supplements if needed</ce:para></ce:list-item><ce:list-item id="u0525"><ce:label>•</ce:label><ce:para id="p0845">If dysphagia persists for &#x003E;48 hrs, start feeding via nasogastric tube</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0245"><ce:section-title id="st0240">Medication</ce:section-title><ce:para id="p0850"><ce:list id="ulist0175"><ce:list-item id="u0530"><ce:label>•</ce:label><ce:para id="p0855">If dysphagic, consider other routes for essential medications</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0250"><ce:section-title id="st0245">Blood pressure</ce:section-title><ce:para id="p0860"><ce:list id="ulist0180"><ce:list-item id="u0535"><ce:label>•</ce:label><ce:para id="p0865">Unless there is heart or renal failure, evidence of hypertensive encephalopathy or aortic dissection, do not lower blood pressure abruptly in first week as it may reduce cerebral perfusion. Blood pressure often returns towards patient's normal level within days</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0255"><ce:section-title id="st0250">Blood glucose</ce:section-title><ce:para id="p0870"><ce:list id="ulist0185"><ce:list-item id="u0540"><ce:label>•</ce:label><ce:para id="p0875">Check blood glucose and treat when levels are ≥11.1 mmol/L (200 mg/dL) (by insulin infusion or glucose/potassium/insulin (GKI)</ce:para></ce:list-item><ce:list-item id="u0545"><ce:label>•</ce:label><ce:para id="p0880">Monitor closely to avoid hypoglycaemia</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0260"><ce:section-title id="st0255">Temperature</ce:section-title><ce:para id="p0885"><ce:list id="ulist0190"><ce:list-item id="u0550"><ce:label>•</ce:label><ce:para id="p0890">If pyrexic, investigate and treat underlying cause</ce:para></ce:list-item><ce:list-item id="u0555"><ce:label>•</ce:label><ce:para id="p0895">Control with antipyretics, as raised brain temperature may increase infarct volume</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0265"><ce:section-title id="st0260">Pressure areas</ce:section-title><ce:para id="p0900"><ce:list id="ulist0195"><ce:list-item id="u0560"><ce:label>•</ce:label><ce:para id="p0905">Reduce risk of skin breakdown:<ce:list id="ulist0200"><ce:list-item id="u0565"><ce:para id="p0910">Treat infection</ce:para></ce:list-item><ce:list-item id="u0570"><ce:para id="p0915">Maintain nutrition</ce:para></ce:list-item><ce:list-item id="u0575"><ce:para id="p0920">Provide pressure-relieving mattress</ce:para></ce:list-item><ce:list-item id="u0580"><ce:para id="p0925">Turn immobile patients regularly</ce:para></ce:list-item></ce:list></ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0270"><ce:section-title id="st0265">Incontinence</ce:section-title><ce:para id="p0930"><ce:list id="ulist0205"><ce:list-item id="u0585"><ce:label>•</ce:label><ce:para id="p0935">Check for constipation and urinary retention; treat these appropriately</ce:para></ce:list-item><ce:list-item id="u0590"><ce:label>•</ce:label><ce:para id="p0940">Avoid urinary catheterisation unless patient is in acute urinary retention or incontinence is threatening pressure areas</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0275"><ce:section-title id="st0270">Mobilisation</ce:section-title><ce:para id="p0945"><ce:list id="ulist0210"><ce:list-item id="u0595"><ce:label>•</ce:label><ce:para id="p0950">Avoid bed rest</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0065" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0135" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000263/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0190" role="short">Image 9</ce:alt-text></ce:inline-figure>26.10</ce:label><ce:alt-text id="atte0195" role="short">26.10</ce:alt-text><ce:textbox-head><ce:title id="tit0070">Causes of cerebral venous thrombosis</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p1055"><ce:display><ce:table frame="topbot" id="t0045"><ce:alt-text id="atte0200" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Predisposing systemic causes</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0220"><ce:list-item id="u0620"><ce:label>•</ce:label><ce:para id="p1060">Dehydration</ce:para></ce:list-item><ce:list-item id="u0625"><ce:label>•</ce:label><ce:para id="p1065">Pregnancy</ce:para></ce:list-item><ce:list-item id="u0630"><ce:label>•</ce:label><ce:para id="p1070">Behçet's disease (<ce:intra-ref id="ii0180" xlink:href="pii:B978-0-7020-7028-0.00024-X#s1580">p. 1043</ce:intra-ref>)</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0225"><ce:list-item id="u0635"><ce:label>•</ce:label><ce:para id="p1075">Thrombophilia (<ce:intra-ref id="ii0185" xlink:href="pii:B978-0-7020-7028-0.00023-8#s0170">p. 922</ce:intra-ref>)</ce:para></ce:list-item><ce:list-item id="u0640"><ce:label>•</ce:label><ce:para id="p1080">Hypotension</ce:para></ce:list-item><ce:list-item id="u0645"><ce:label>•</ce:label><ce:para id="p1085">Oral contraceptive use</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Local causes</ce:bold></entry></row><row><entry align="left"><ce:list id="ulist0230"><ce:list-item id="u0650"><ce:label>•</ce:label><ce:para id="p1090">Paranasal sinusitis</ce:para></ce:list-item><ce:list-item id="u0655"><ce:label>•</ce:label><ce:para id="p1095">Meningitis, subdural empyema</ce:para></ce:list-item><ce:list-item id="u0660"><ce:label>•</ce:label><ce:para id="p1100">Penetrating head and eye wounds</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0235"><ce:list-item id="u0665"><ce:label>•</ce:label><ce:para id="p1105">Facial skin infection</ce:para></ce:list-item><ce:list-item id="u0670"><ce:label>•</ce:label><ce:para id="p1110">Otitis media, mastoiditis</ce:para></ce:list-item><ce:list-item id="u0675"><ce:label>•</ce:label><ce:para id="p1115">Skull fracture</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0070" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0140" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000263/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0205" role="short">Image 10</ce:alt-text></ce:inline-figure>26.11</ce:label><ce:alt-text id="atte0210" role="short">26.11</ce:alt-text><ce:textbox-head><ce:title id="tit0075">Clinical features of cerebral venous thrombosis</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s0345"><ce:section-title id="st0340">Cavernous sinus thrombosis</ce:section-title><ce:para id="p1125"><ce:list id="ulist0240"><ce:list-item id="u0680"><ce:label>•</ce:label><ce:para id="p1130">Proptosis, ptosis, headache, external and internal ophthalmoplegia, papilloedema, reduced sensation in trigeminal first division</ce:para></ce:list-item><ce:list-item id="u0685"><ce:label>•</ce:label><ce:para id="p1135">Often bilateral, patient ill and febrile</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0350"><ce:section-title id="st0345">Superior sagittal sinus thrombosis</ce:section-title><ce:para id="p1140"><ce:list id="ulist0245"><ce:list-item id="u0690"><ce:label>•</ce:label><ce:para id="p1145">Headache, papilloedema, seizures</ce:para></ce:list-item><ce:list-item id="u0695"><ce:label>•</ce:label><ce:para id="p1150">Clinical features may resemble idiopathic intracranial hypertension (<ce:intra-ref id="ii0190" xlink:href="pii:B978-0-7020-7028-0.00025-1#s1815">p. 1133</ce:intra-ref>)</ce:para></ce:list-item><ce:list-item id="u0700"><ce:label>•</ce:label><ce:para id="p1155">May involve veins of both hemispheres, causing advancing motor and sensory focal deficits</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0355"><ce:section-title id="st0350">Transverse sinus thrombosis</ce:section-title><ce:para id="p1160"><ce:list id="ulist0250"><ce:list-item id="u0705"><ce:label>•</ce:label><ce:para id="p1165">Hemiparesis, seizures, papilloedema</ce:para></ce:list-item><ce:list-item id="u0710"><ce:label>•</ce:label><ce:para id="p1170">May spread to jugular foramen and involve cranial nerves 9, 10 and 11</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox></ce:floats><ce:label>26</ce:label><ce:title id="tit0010">Stroke medicine</ce:title><ce:author-group id="aug0010"><ce:author author-id="B9780702070280000263-443ddb3025c02a1b8645387d550b80a8" id="au0010"><ce:given-name>P</ce:given-name><ce:surname>Langhorne</ce:surname></ce:author></ce:author-group><outline id="out0010"><ce:list id="ulist0010"><ce:list-item id="u0010"><ce:para id="p0010"><ce:bold>Clinical examination in stroke disease</ce:bold> <ce:cross-ref id="crf0010" refid="s0010"><ce:bold>1148</ce:bold></ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0015"><ce:para id="p0015"><ce:bold>Functional anatomy and physiology</ce:bold> <ce:cross-ref id="crf0015" refid="s0075"><ce:bold>1150</ce:bold></ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0020"><ce:para id="p0020"><ce:bold>Investigations</ce:bold> <ce:cross-ref id="crf0020" refid="s0080"><ce:bold>1151</ce:bold></ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0025"><ce:para id="p0025"><ce:bold>Presenting problems</ce:bold> <ce:cross-ref id="crf0025" refid="s0115"><ce:bold>1152</ce:bold></ce:cross-ref><ce:list id="ulist0015"><ce:list-item id="u0030"><ce:para id="p0030">Weakness <ce:cross-ref id="crf0030" refid="s0120">1152</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0035"><ce:para id="p0035">Speech disturbance <ce:cross-ref id="crf0035" refid="s0125">1152</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0040"><ce:para id="p0040">Visual deficit <ce:cross-ref id="crf0040" refid="s0130">1152</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0045"><ce:para id="p0045">Visuo-spatial dysfunction <ce:cross-ref id="crf0045" refid="s0135">1152</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0050"><ce:para id="p0050">Ataxia <ce:cross-ref id="crf0050" refid="s0140">1153</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0055"><ce:para id="p0055">Headache <ce:cross-ref id="crf0055" refid="s0145">1153</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0060"><ce:para id="p0060">Seizure <ce:cross-ref id="crf0060" refid="s0150">1153</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0065"><ce:para id="p0065">Coma <ce:cross-ref id="crf0065" refid="s0155">1153</ce:cross-ref></ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u0070"><ce:para id="p0070"><ce:bold>Stroke</ce:bold> <ce:cross-ref id="crf0070" refid="s0160"><ce:bold>1153</ce:bold></ce:cross-ref><ce:list id="ulist0020"><ce:list-item id="u0075"><ce:para id="p0075">Pathophysiology <ce:cross-ref id="crf0075" refid="s0165">1153</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0080"><ce:para id="p0080">Clinical features <ce:cross-ref id="crf0080" refid="s0180">1155</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0085"><ce:para id="p0085">Investigations <ce:cross-ref id="crf0085" refid="s0185">1157</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0090"><ce:para id="p0090">Management <ce:cross-ref id="crf0090" refid="s0210">1158</ce:cross-ref></ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u0095"><ce:para id="p0095"><ce:bold>Subarachnoid haemorrhage</ce:bold> <ce:cross-ref id="crf0095" refid="s0315"><ce:bold>1160</ce:bold></ce:cross-ref><ce:list id="ulist0025"><ce:list-item id="u0100"><ce:para id="p0100">Clinical features <ce:cross-ref id="crf0100" refid="s0320">1161</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0105"><ce:para id="p0105">Investigations <ce:cross-ref id="crf0105" refid="s0325">1161</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0110"><ce:para id="p0110">Management <ce:cross-ref id="crf0110" refid="s0330">1162</ce:cross-ref></ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u0115"><ce:para id="p0115"><ce:bold>Cerebral venous disease</ce:bold> <ce:cross-ref id="crf0115" refid="s0335"><ce:bold>1162</ce:bold></ce:cross-ref><ce:list id="ulist0030"><ce:list-item id="u0120"><ce:para id="p0120">Clinical features <ce:cross-ref id="crf0120" refid="s0340">1162</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0125"><ce:para id="p0125">Investigations and management <ce:cross-ref id="crf0125" refid="s0360">1162</ce:cross-ref></ce:para></ce:list-item></ce:list></ce:para></ce:list-item></ce:list></outline><ce:sections><ce:section id="s0010"><ce:section-title id="st0010">Clinical examination in stroke disease</ce:section-title><ce:para id="p0130"><ce:display><ce:figure id="f0010"><ce:alt-text id="atte0215" role="short">Unlabelled image</ce:alt-text><ce:link id="ln0010" locator="u026-001-9780702070280" xlink:href="pii:B9780702070280000263/u026-001-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure></ce:display><ce:display><ce:textbox id="b0010" role="alt1"><ce:alt-text id="atte0220" role="short">Unlabelled box</ce:alt-text><ce:textbox-head><ce:title id="tit0015"><ce:inline-figure baseline="0.0"><ce:link id="ln9000" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000263/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0225" role="short">Image 11</ce:alt-text></ce:inline-figure>General examination</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s0015"><ce:section-title id="st0015">Skin</ce:section-title><ce:para id="p0135"><ce:list id="ulist0035"><ce:list-item id="u0130"><ce:label>•</ce:label><ce:para id="p0140">Xanthelasma</ce:para></ce:list-item><ce:list-item id="u0135"><ce:label>•</ce:label><ce:para id="p0145">Rash (arteritis, splinter haemorrhages)</ce:para></ce:list-item><ce:list-item id="u0140"><ce:label>•</ce:label><ce:para id="p0150">Colour change (limb ischaemia, deep vein thrombosis)</ce:para></ce:list-item><ce:list-item id="u0145"><ce:label>•</ce:label><ce:para id="p0155">Pressure injury</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0020"><ce:section-title id="st0020">Eyes</ce:section-title><ce:para id="p0160"><ce:list id="ulist0040"><ce:list-item id="u0150"><ce:label>•</ce:label><ce:para id="p0165">Arcus senilis</ce:para></ce:list-item><ce:list-item id="u0155"><ce:label>•</ce:label><ce:para id="p0170">Diabetic retinopathy</ce:para></ce:list-item><ce:list-item id="u0160"><ce:label>•</ce:label><ce:para id="p0175">Hypertensive retinopathy</ce:para></ce:list-item><ce:list-item id="u0165"><ce:label>•</ce:label><ce:para id="p0180">Retinal emboli</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0025"><ce:section-title id="st0025">Cardiovascular system</ce:section-title><ce:para id="p0185"><ce:list id="ulist0045"><ce:list-item id="u0170"><ce:label>•</ce:label><ce:para id="p0190">Heart rhythm (?atrial fibrillation)</ce:para></ce:list-item><ce:list-item id="u0175"><ce:label>•</ce:label><ce:para id="p0195">Blood pressure (high or low)</ce:para></ce:list-item><ce:list-item id="u0180"><ce:label>•</ce:label><ce:para id="p0200">Carotid bruit</ce:para></ce:list-item><ce:list-item id="u0185"><ce:label>•</ce:label><ce:para id="p0205">Jugular venous pulse (raised in heart failure, low in hypovolaemia)</ce:para></ce:list-item><ce:list-item id="u0190"><ce:label>•</ce:label><ce:para id="p0210">Murmurs (source of embolism)</ce:para></ce:list-item><ce:list-item id="u0195"><ce:label>•</ce:label><ce:para id="p0215">Peripheral pulses and bruits (?generalised arteriopathy)</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0030"><ce:section-title id="st0030">Respiratory system</ce:section-title><ce:para id="p0220"><ce:list id="ulist0050"><ce:list-item id="u0200"><ce:label>•</ce:label><ce:para id="p0225">Signs of pulmonary oedema or infection</ce:para></ce:list-item><ce:list-item id="u0205"><ce:label>•</ce:label><ce:para id="p0230">Oxygen saturation</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0035"><ce:section-title id="st0035">Abdomen</ce:section-title><ce:para id="p0235"><ce:list id="ulist0055"><ce:list-item id="u0210"><ce:label>•</ce:label><ce:para id="p0240">Palpable bladder (urinary retention)</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0040"><ce:section-title id="st0040">Locomotor system</ce:section-title><ce:para id="p0245"><ce:list id="ulist0060"><ce:list-item id="u0215"><ce:label>•</ce:label><ce:para id="p0250">Injuries sustained during collapse</ce:para></ce:list-item><ce:list-item id="u0220"><ce:label>•</ce:label><ce:para id="p0255">Comorbidities that influence recovery, e.g. osteoarthritis</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox></ce:display><ce:display><ce:textbox id="b0015" role="alt1"><ce:alt-text id="atte0230" role="short">Unlabelled box</ce:alt-text><ce:textbox-head><ce:title id="tit0020"><ce:inline-figure baseline="0.0"><ce:link id="ln9005" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000263/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0235" role="short">Image 12</ce:alt-text></ce:inline-figure>Rapid assessment of suspected stroke</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s0045"><ce:section-title id="st0045">Rosier scale</ce:section-title><ce:para id="p0260">Can be used by emergency staff to indicate probability of a stroke in acute presentations:<ce:display><ce:table frame="topbot" id="t0010"><ce:alt-text id="atte0240" role="short">Unlabelled table</ce:alt-text><tgroup cols="4"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><colspec colname="col4" colnum="4"/><tbody><row rowsep="0"><entry align="left">Unilateral facial weakness</entry><entry align="left">+1</entry><entry align="left">Loss of consciousness</entry><entry align="left">−1</entry></row><row rowsep="0"><entry align="left">Unilateral grip weakness</entry><entry align="left">+1</entry><entry align="left">Seizure</entry><entry align="left">−1</entry></row><row rowsep="0"><entry align="left">Unilateral arm weakness</entry><entry align="left">+1</entry><entry align="left"/><entry align="left"/></row><row rowsep="0"><entry align="left">Unilateral leg weakness</entry><entry align="left">+1</entry><entry align="left"/><entry align="left"/></row><row rowsep="0"><entry align="left">Speech loss</entry><entry align="left">+1</entry><entry align="left"/><entry align="left"/></row><row><entry align="left">Visual field defect</entry><entry align="left">+1</entry><entry align="left"/><entry align="left"/></row></tbody></tgroup></ce:table></ce:display></ce:para><ce:para id="p0265">Total (−2 to +6); score of &#x003E; 0 indicates stroke is possible cause</ce:para></ce:section><ce:section id="s0050"><ce:section-title id="st0050">Exclusion of hypoglycaemia</ce:section-title><ce:para id="p0270"><ce:list id="ulist0065"><ce:list-item id="u0225"><ce:label>•</ce:label><ce:para id="p0275">Bedside blood glucose testing with BMstix</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0055"><ce:section-title id="st0055">Language deficit</ce:section-title><ce:para id="p0280"><ce:list id="ulist0070"><ce:list-item id="u0230"><ce:label>•</ce:label><ce:para id="p0285">History and examination may indicate a language deficit</ce:para></ce:list-item><ce:list-item id="u0235"><ce:label>•</ce:label><ce:para id="p0290">Check comprehension (‘lift your arms, close your eyes’) to identify a receptive dysphasia</ce:para></ce:list-item><ce:list-item id="u0240"><ce:label>•</ce:label><ce:para id="p0295">Ask patient to name people/objects (e.g. nurse, watch, pen) to identify a nominal dysphasia</ce:para></ce:list-item><ce:list-item id="u0245"><ce:label>•</ce:label><ce:para id="p0300">Check articulation (ask patient to repeat phrases after you) for dysarthria</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0060"><ce:section-title id="st0060">Motor deficit</ce:section-title><ce:para id="p0305">Subtle pyramidal signs:<ce:list id="ulist0075"><ce:list-item id="u0250"><ce:label>•</ce:label><ce:para id="p0310">Check for pronator drift: ask patient to hold out arms and maintain their position with eyes closed (see opposite)</ce:para></ce:list-item><ce:list-item id="u0255"><ce:label>•</ce:label><ce:para id="p0315">Check for clumsiness of fine finger movements</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0065"><ce:section-title id="st0065">Sensory and visual inattention</ce:section-title><ce:para id="p0320"><ce:list id="ulist0080"><ce:list-item id="u0260"><ce:label>•</ce:label><ce:para id="p0325">Establish that sensation/visual field is intact on testing one side at a time</ce:para></ce:list-item><ce:list-item id="u0265"><ce:label>•</ce:label><ce:para id="p0330">Retest sensation/visual fields on simultaneous testing of both sides; the affected side will no longer be felt/seen</ce:para></ce:list-item><ce:list-item id="u0270"><ce:label>•</ce:label><ce:para id="p0335">Perform clock drawing test (see below)</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0070"><ce:section-title id="st0070">Truncal ataxia</ce:section-title><ce:para id="p0340"><ce:list id="ulist0085"><ce:list-item id="u0275"><ce:label>•</ce:label><ce:para id="p0345">Check if patient can sit up or stand without support</ce:para></ce:list-item></ce:list><ce:display><ce:figure id="f0015"><ce:caption id="ca0010"><ce:simple-para id="sp0010" role="title">Clock drawing test</ce:simple-para><ce:simple-para id="sp0015" role="caption"><ce:bold>A</ce:bold> An image drawn by a doctor. <ce:bold>B</ce:bold> An image drawn by a patient with left-sided neglect.</ce:simple-para></ce:caption><ce:alt-text id="atte0245" role="short">Unlabelled image</ce:alt-text><ce:link id="ln0015" locator="u026-002-9780702070280" xlink:href="pii:B9780702070280000263/u026-002-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure></ce:display></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox></ce:display></ce:para></ce:section><ce:para id="p0350">Cerebrovascular disease is the third most common cause of death in high-income countries after cancers and ischaemic heart disease, and the most common cause of severe physical disability. It includes a range of disorders of the central nervous system (<ce:cross-ref id="crf0130" refid="f0020">Fig. 26.1</ce:cross-ref><ce:float-anchor refid="f0020"/>). Stroke is the most common clinical manifestation of cerebrovascular disease and results in episodes of brain dysfunction due to focal ischaemia or haemorrhage. Subarachnoid haemorrhage (SAH) and cerebral venous thrombosis (CVT) will be discussed separately, since their pathophysiology, clinical manifestations and management are distinct from those of stroke. Vascular dementia is described on <ce:intra-ref id="ii0010" xlink:href="pii:B978-0-7020-7028-0.00028-7#s0480">page 1191</ce:intra-ref>.</ce:para><ce:section id="s0075"><ce:section-title id="st0075">Functional anatomy and physiology</ce:section-title><ce:para id="p0355">The main arterial supply of the brain comes from the internal carotid arteries, which supply the anterior brain through the anterior and middle cerebral arteries, and the vertebral and basilar arteries (vertebrobasilar system), which provide the posterior circulation to the posterior cerebral arteries. The anterior and middle cerebral arteries supply the frontal and parietal lobes, while the posterior cerebral artery supplies the occipital lobe. The vertebral and basilar arteries perfuse the brainstem, mid-brain and cerebellum (<ce:cross-ref id="crf0135" refid="f0025">Fig. 26.2</ce:cross-ref><ce:float-anchor refid="f0025"/>). The functions of each of these areas of the brain are described on <ce:intra-ref id="ii0015" xlink:href="pii:B978-0-7020-7028-0.00025-1#s0015">page 1064</ce:intra-ref>. Communicating arteries provide connections between the anterior and posterior circulations and between left and right hemispheres, creating protective anastomotic connections that form the circle of Willis. In health, regulatory mechanisms maintain a constant cerebral blood flow across a wide range of arterial blood pressures to meet the high resting metabolic activity of brain tissue; cerebral blood vessels dilate when systemic blood pressure is lowered and constrict when it is raised. This autoregulatory mechanism can be disrupted after stroke. The venous collecting system is formed by a collection of sinuses over the surface of the brain, which drain into the jugular veins (<ce:cross-ref id="crf0140" refid="f0030">Fig. 26.3</ce:cross-ref><ce:float-anchor refid="f0030"/>).</ce:para></ce:section><ce:section id="s0080"><ce:section-title id="st0080">Investigations</ce:section-title><ce:para id="p0360">A range of investigations may be required to answer specific questions about brain structure and function and about the function of the vascular system.</ce:para><ce:section id="s0085"><ce:section id="s0090"><ce:section-title id="st0085">Neuroimaging</ce:section-title><ce:para id="p0365">Computed tomography (CT) scanning is the mainstay of emergency stroke imaging. It allows the rapid identification of intracerebral bleeding and stroke ‘mimics’ (i.e. pathologies other than stroke that have similar presentations), such as tumours. Magnetic resonance imaging (MRI) is used when there is diagnostic uncertainty or delayed presentation, and when more information on brain structure and function is required (<ce:cross-ref id="crf0145" refid="f0035">Fig. 26.4</ce:cross-ref><ce:float-anchor refid="f0035"/>). Contraindications to MRI include cardiac pacemakers and claustrophobia on entering the scanner. CT angiography (CTA) and CT perfusion are now being used to characterise the cerebral circulation and areas of ischaemia better (<ce:intra-ref id="ii0020" xlink:href="pii:B978-0-7020-7028-0.00025-1#p1085">p. 1072</ce:intra-ref>).</ce:para></ce:section><ce:section id="s0095"><ce:section-title id="st0090">Vascular imaging</ce:section-title><ce:para id="p0370">Various techniques are used to obtain images of extracranial and intracranial blood vessels (<ce:cross-ref id="crf0150" refid="f0040">Fig. 26.5</ce:cross-ref><ce:float-anchor refid="f0040"/>). The least invasive is ultrasound (Doppler or duplex scanning), which is used to image the carotid and the vertebral arteries in the neck. In skilled hands, reliable information can be provided about the degree of arterial stenosis and the presence of ulcerated plaques. Blood flow in the intracerebral vessels can be examined using transcranial Doppler. While the anatomical resolution is limited, it is improving and many centres no longer require formal angiography before proceeding to carotid endarterectomy (see below). Blood flow can also be detected by specialised sequences in MR angiography (MRA) or CTA but the anatomical resolution is still not as good as that of intra-arterial angiography, which outlines blood vessels by the injection of radio-opaque contrast intravenously or intra-arterially. The X-ray images obtained can be enhanced by the use of computer-assisted digital subtraction or spiral CT. Because of the significant risk of complications, intra-arterial contrast angiography is reserved for use when non-invasive methods have provided a contradictory picture or incomplete information, or when it is necessary to image the intracranial circulation in detail, e.g. to delineate a saccular aneurysm, an arteriovenous malformation or vasculitis.</ce:para></ce:section><ce:section id="s0100"><ce:section-title id="st0095">Blood tests</ce:section-title><ce:para id="p0375">These identify underlying causes of cerebrovascular disease, e.g. blood glucose (diabetes mellitus), triglycerides and cholesterol (hyperlipidaemia) or full blood count (polycythaemia). Erythrocyte sedimentation rate (ESR) and immunological tests, such as antineutrophil cytoplasmic antibodies (ANCAs, <ce:intra-ref id="ii0025" xlink:href="pii:B978-0-7020-7028-0.00024-X#s0170">p. 992</ce:intra-ref>), may be required when vasculitis is suspected. Genetic testing for rarer inherited conditions, such as CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy), may be indicated.</ce:para></ce:section><ce:section id="s0105"><ce:section-title id="st0100">Lumbar puncture</ce:section-title><ce:para id="p0380">Lumbar puncture (<ce:intra-ref id="ii0030" xlink:href="pii:B978-0-7020-7028-0.00025-1#s0185">p. 1077</ce:intra-ref>) is reserved for investigation of SAH.</ce:para></ce:section><ce:section id="s0110"><ce:section-title id="st0105">Cardiovascular investigations</ce:section-title><ce:para id="p0385">Electrocardiography (ECG; <ce:intra-ref id="ii0035" xlink:href="pii:B978-0-7020-7028-0.00016-0#s0085">p. 448</ce:intra-ref>), including ECG monitoring and echocardiography (<ce:intra-ref id="ii0040" xlink:href="pii:B978-0-7020-7028-0.00016-0#s0140">p. 451</ce:intra-ref>), may reveal abnormalities that may cause cardiac embolism in stroke.</ce:para></ce:section></ce:section></ce:section><ce:section id="s0115"><ce:section-title id="st0110">Presenting problems</ce:section-title><ce:para id="p0390">Most vascular lesions develop suddenly within a matter of minutes or hours, and so should be considered in the differential diagnosis of patients with any acute neurological presentation.</ce:para><ce:section id="s0120"><ce:section-title id="st0115">Weakness</ce:section-title><ce:para id="p0395">Unilateral weakness is the classical presentation of stroke and, much more rarely, of CVT. The weakness is sudden, progresses rapidly and follows a hemiplegic pattern (see <ce:intra-ref id="ii0045" xlink:href="pii:B978-0-7020-7028-0.00025-1#f0115">Fig. 25.17</ce:intra-ref>, <ce:intra-ref id="ii0050" xlink:href="pii:B978-0-7020-7028-0.00025-1#s0325">p. 1082</ce:intra-ref>). There is rarely any associated abnormal movement. Reflexes are initially reduced but then become increased with a spastic pattern of increased tone (see <ce:intra-ref id="ii0055" xlink:href="pii:B978-0-7020-7028-0.00025-1#b0090">Box 25.14</ce:intra-ref>, <ce:intra-ref id="ii0060" xlink:href="pii:B978-0-7020-7028-0.00025-1#s0325">p. 1082</ce:intra-ref>). Upper motor neuron weakness of the face (7th cranial nerve) is often present.</ce:para></ce:section><ce:section id="s0125"><ce:section-title id="st0120">Speech disturbance</ce:section-title><ce:para id="p0400">Dysphasia and dysarthria are the most common presentations of disturbed speech in stroke (<ce:intra-ref id="ii0065" xlink:href="pii:B978-0-7020-7028-0.00025-1#s0450">p. 1087</ce:intra-ref>). Dysphasia indicates damage to the dominant frontal or parietal lobe (see <ce:intra-ref id="ii0070" xlink:href="pii:B978-0-7020-7028-0.00025-1#b0030">Box 25.2</ce:intra-ref>, <ce:intra-ref id="ii0075" xlink:href="pii:B978-0-7020-7028-0.00025-1#s0040">p. 1066</ce:intra-ref>), while dysarthria is a non-localising feature that reflects weakness or incoordination of the face, pharynx, lips, tongue or palate.</ce:para></ce:section><ce:section id="s0130"><ce:section-title id="st0125">Visual deficit</ce:section-title><ce:para id="p0405">Visual loss can be due to unilateral optic ischaemia (called amaurosis fugax if transient), caused by disturbance of blood flow in the internal carotid artery and ophthalmic artery, leading to monocular blindness. Ischaemia of the occipital cortex or post-chiasmic nerve tracts results in a contralateral hemianopia (<ce:intra-ref id="ii0080" xlink:href="pii:B978-0-7020-7028-0.00025-1#s0495">p. 1088</ce:intra-ref>).</ce:para></ce:section><ce:section id="s0135"><ce:section-title id="st0130">Visuo-spatial dysfunction</ce:section-title><ce:para id="p0410">Damage to the non-dominant cortex often results in contralateral visuo-spatial dysfunction, e.g. sensory or visual neglect and apraxia (inability to perform complex tasks despite normal motor, sensory and cerebellar function; <ce:intra-ref id="ii0085" xlink:href="pii:B978-0-7020-7028-0.00025-1#s0395">p. 1086</ce:intra-ref>), sometimes misdiagnosed as delirium.</ce:para></ce:section><ce:section id="s0140"><ce:section-title id="st0135">Ataxia</ce:section-title><ce:para id="p0415">Stroke causing damage to the cerebellum and its connections can present as an acute ataxia (<ce:intra-ref id="ii0090" xlink:href="pii:B978-0-7020-7028-0.00025-1#s0395">p. 1086</ce:intra-ref>) and there may be associated brainstem features such as diplopia (<ce:intra-ref id="ii0095" xlink:href="pii:B978-0-7020-7028-0.00025-1#s0495">p. 1088</ce:intra-ref>) and vertigo (<ce:intra-ref id="ii0100" xlink:href="pii:B978-0-7020-7028-0.00025-1#s0395">p. 1086</ce:intra-ref>). The differential diagnosis includes vestibular disorders (<ce:intra-ref id="ii0105" xlink:href="pii:B978-0-7020-7028-0.00025-1#s0895">p. 1104</ce:intra-ref>).</ce:para></ce:section><ce:section id="s0145"><ce:section-title id="st0140">Headache</ce:section-title><ce:para id="p0420">Sudden severe headache is the cardinal symptom of SAH but also occurs in intracerebral haemorrhage. Although headache is common in acute ischaemic stroke, it is rarely a dominant feature (<ce:intra-ref id="ii0110" xlink:href="pii:B978-0-7020-7028-0.00025-1#s0245">p. 1080</ce:intra-ref>). Headache also occurs in cerebral venous disease.</ce:para></ce:section><ce:section id="s0150"><ce:section-title id="st0145">Seizure</ce:section-title><ce:para id="p0425">Seizure is unusual in acute stroke but may be generalised or focal (especially in cerebral venous disease).</ce:para></ce:section><ce:section id="s0155"><ce:section-title id="st0150">Coma</ce:section-title><ce:para id="p0430">Coma is uncommon, though it may occur with a brainstem event. If present in the first 24 hours, it usually indicates a subarachnoid or intracerebral haemorrhage (see <ce:intra-ref id="ii0115" xlink:href="pii:B978-0-7020-7028-0.00010-X#b0140">Box 10.26</ce:intra-ref>, <ce:intra-ref id="ii0120" xlink:href="pii:B978-0-7020-7028-0.00010-X#s0425">p. 194</ce:intra-ref>).</ce:para></ce:section></ce:section><ce:section id="s0160"><ce:section-title id="st0155">Stroke</ce:section-title><ce:para id="p0435">Stroke is a common medical emergency. The incidence rises steeply with age, and in many lower- and middle-income countries it is rising in association with less healthy lifestyles. About 20% of stroke patients die within a month of the event and at least half of those who survive are left with physical disability.</ce:para><ce:section id="s0165"><ce:section-title id="st0160">Pathophysiology</ce:section-title><ce:para id="p0440">Of the 180–300 patients per 100 000 population presenting annually with a stroke, 85% sustain a cerebral infarction due to inadequate blood flow to part of the brain, and most of the remainder have an intracerebral haemorrhage (see <ce:cross-ref id="crf0155" refid="f0020">Fig. 26.1</ce:cross-ref>).</ce:para><ce:section id="s0170"><ce:section-title id="st0165">Cerebral infarction</ce:section-title><ce:para id="p0445">Cerebral infarction is mostly caused by thromboembolic disease secondary to atherosclerosis in the major extracranial arteries (carotid artery and aortic arch). About 20% of infarctions are due to embolism from the heart, and a further 20% are due to thrombosis in situ caused by intrinsic disease of small perforating vessels (lenticulostriate arteries), producing so-called lacunar infarctions. The risk factors for ischaemic stroke reflect the risk factors for the underlying vascular disease (<ce:cross-ref id="crf0160" refid="b0020">Box 26.1</ce:cross-ref><ce:float-anchor refid="b0020"/>). About 5% are due to rare causes, including vasculitis (<ce:intra-ref id="ii0125" xlink:href="pii:B978-0-7020-7028-0.00024-X#p5220">p. 1040</ce:intra-ref>), endocarditis (<ce:intra-ref id="ii0130" xlink:href="pii:B978-0-7020-7028-0.00016-0#s2365">p. 527</ce:intra-ref>) and cerebral venous disease (see below). Cerebral infarction takes some hours to complete, even though the patient's deficit may be maximal shortly after the vascular occlusion. After the occlusion of a cerebral artery, infarction may be forestalled by the opening of anastomotic channels from other arterial territories that restore perfusion to its territory. Similarly, reduction in perfusion pressure leads to compensatory homeostatic changes to maintain tissue oxygenation (<ce:cross-ref id="crf0165" refid="f0045">Fig. 26.6</ce:cross-ref><ce:float-anchor refid="f0045"/>). These compensatory changes can sometimes prevent occlusion of even a carotid artery from having any clinically apparent effect.</ce:para><ce:para id="p0570">However, if and when these homeostatic mechanisms fail, the process of ischaemia starts, and ultimately leads to infarction unless the vascular supply is restored. As the cerebral blood flow declines, different neuronal functions fail at various thresholds (<ce:cross-ref id="crf0170" refid="f0050">Fig. 26.7</ce:cross-ref><ce:float-anchor refid="f0050"/>). Once blood flow falls below the threshold for the maintenance of electrical activity, neurological deficit develops. At this level of blood flow, neurons are still viable; if blood flow increases again, function returns and the patient will have had a transient ischaemic attack (TIA). However, if blood flow falls further, a level is reached at which irreversible cell death starts. Hypoxia leads to an inadequate supply of adenosine triphosphate (ATP), which leads to failure of membrane pumps, thereby allowing influx of sodium and water into cells (cytotoxic oedema) and release of the excitatory neurotransmitter glutamate into the extracellular fluid. Glutamate opens membrane channels, allowing influx of calcium and more sodium into the neurons. Calcium activates intracellular enzymes that complete the destructive process. The release of inflammatory mediators by microglia and astrocytes causes death of all cell types in the area of maximum ischaemia. The infarction process is worsened by anaerobic production of lactic acid (<ce:cross-ref id="crf0175" refid="f0055">Fig. 26.8</ce:cross-ref><ce:float-anchor refid="f0055"/>) and consequent fall in tissue pH. There have been attempts to develop neuroprotective drugs to slow down the processes leading to irreversible cell death but so far these have proved disappointing.</ce:para><ce:para id="p0575">The final outcome of occlusion of a cerebral blood vessel thus depends on the competence of circulatory homeostatic mechanisms, the metabolic demand, and the severity and duration of the reduction in blood flow. Higher brain temperature, e.g. in fever, and higher blood glucose have both been associated with a greater volume of infarction for a given reduction in cerebral blood flow. Subsequent restoration of blood flow may cause haemorrhage into the infarcted area (‘haemorrhagic transformation’). This is particularly likely in patients given antithrombotic or thrombolytic drugs, and in patients with larger infarcts.</ce:para><ce:para id="p0580">Radiologically, a cerebral infarct can be seen as a lesion that comprises a mixture of dead brain tissue that is already undergoing autolysis, and tissue that is ischaemic and swollen but recoverable (the ‘ischaemic penumbra’). The infarct swells with time and is at its maximal size a couple of days after stroke onset. At this stage, it may be big enough to exert mass effect both clinically and radiologically; sometimes, decompressive craniectomy is required (see below). After a few weeks, the oedema subsides and the infarcted area is replaced by a sharply defined fluid-filled cavity.</ce:para></ce:section><ce:section id="s0175"><ce:section-title id="st0170">Intracerebral haemorrhage</ce:section-title><ce:para id="p0585">Intracerebral haemorrhage causes about 10% of acute stroke events but is more common in low-income countries. It usually results from rupture of a blood vessel within the brain parenchyma but may also occur in a patient with SAH (see below) if the artery ruptures into the brain substance as well as the subarachnoid space. Haemorrhage frequently occurs into an area of brain infarction and, if the volume of haemorrhage is large, it may be difficult to distinguish from primary intracerebral haemorrhage both clinically and radiologically (<ce:cross-ref id="crf0180" refid="f0060">Fig. 26.9</ce:cross-ref><ce:float-anchor refid="f0060"/>). The risk factors and underlying causes of intracerebral haemorrhage are listed in <ce:cross-ref id="crf0185" refid="b0025">Box 26.2</ce:cross-ref><ce:float-anchor refid="b0025"/>. Explosive entry of blood into the brain parenchyma causes immediate cessation of function in that area as neurons are disrupted and white-matter fibre tracts are split apart. The haemorrhage itself may expand over the first minutes or hours, or it may be associated with a rim of cerebral oedema, which, along with the haematoma, acts like a mass lesion to cause progression of the neurological deficit. If big enough, this can cause shift of the intracranial contents, producing transtentorial coning and sometimes rapid death (<ce:intra-ref id="ii0135" xlink:href="pii:B978-0-7020-7028-0.00025-1#p8080">p. 1127</ce:intra-ref>). If the patient survives, the haematoma is gradually absorbed, leaving a haemosiderin-lined slit in the brain parenchyma.</ce:para></ce:section></ce:section><ce:section id="s0180"><ce:section-title id="st0175">Clinical features</ce:section-title><ce:para id="p0595">Both acute stroke and transient ischaemic attack (TIA) are characterised by a rapid-onset, focal deficit of brain function and can be considered as a spectrum of symptoms from transient (TIA) to persistent (stroke). The typical presentation occurs over minutes, affects an identifiable area of brain and is ‘negative’ in character (i.e. abrupt loss of function without positive features such as abnormal movement). Provided there is a clear history of this, the chance of a brain lesion being anything other than vascular is 5% or less (<ce:cross-ref id="crf0190" refid="b0030">Box 26.3</ce:cross-ref><ce:float-anchor refid="b0030"/>). If symptoms progress over hours or days, other diagnoses must be excluded. Delirium and memory or balance disturbance are more often due to stroke mimics. Transient symptoms, e.g. syncope, amnesia, delirium and dizziness, do not reflect focal cerebral dysfunction but are often mistakenly attributed to TIA (see <ce:intra-ref id="ii0145" xlink:href="pii:B978-0-7020-7028-0.00010-X#f0035">Fig. 10.3</ce:intra-ref>, <ce:intra-ref id="ii0150" xlink:href="pii:B978-0-7020-7028-0.00010-X#s0130">p. 182</ce:intra-ref>, and <ce:cross-ref id="crf0195" refid="b0035">Box 26.4</ce:cross-ref><ce:float-anchor refid="b0035"/>). Campaigns to raise public awareness of the emergency nature of stroke exploit the fact that weakness of the face or arm, or disturbance of speech is the most common presentation.</ce:para><ce:para id="p0675">The clinical presentation of stroke depends on which arterial territory is involved and the size of the lesion (see <ce:cross-ref id="crf0200" refid="f0020">Fig. 26.1</ce:cross-ref>). These will both have a bearing on management, such as suitability for carotid endarterectomy. The neurological deficit can be identified from the patient's history and (if it is persistent) the neurological examination. The presence of a unilateral motor deficit, a higher cerebral function deficit such as aphasia or neglect, or a visual field defect usually places the lesion in the cerebral hemisphere. Ataxia, diplopia, vertigo and/or bilateral weakness usually indicate a lesion in the brainstem or cerebellum. Different combinations of these deficits define several stroke syndromes (<ce:cross-ref id="crf0205" refid="f0065">Fig. 26.10</ce:cross-ref><ce:float-anchor refid="f0065"/>), which reflect the site and size of the lesion and may provide clues to the underlying pathology.</ce:para><ce:para id="p0680">Reduced conscious level usually indicates a large-volume lesion in the cerebral hemisphere but may result from a lesion in the brainstem or complications such as obstructive hydrocephalus, hypoxia or severe systemic infection. The combination of severe headache and vomiting at the onset of the focal deficit is suggestive of intracerebral haemorrhage.</ce:para><ce:para id="p0685">General examination may provide clues to the cause and identify important comorbidities and complications.</ce:para><ce:para id="p0690">Several terms have been used to classify strokes, often based on the duration and evolution of symptoms:<ce:list id="ulist0140"><ce:list-item id="u0460"><ce:label>•</ce:label><ce:para id="p0695"><ce:italic>Transient ischaemic attack (TIA)</ce:italic> describes a stroke in which symptoms resolve within 24 hours – an arbitrary cut-off that has little value in practice, apart from perhaps indicating that underlying cerebral haemorrhage or extensive cerebral infarction is extremely unlikely. The term TIA traditionally also includes patients with amaurosis fugax, usually due to a vascular occlusion in the retina.</ce:para></ce:list-item><ce:list-item id="u0465"><ce:label>•</ce:label><ce:para id="p0700"><ce:italic>Stroke</ce:italic> describes those events in which symptoms last more than 24 hours. The differential diagnosis of patients with symptoms lasting a few minutes or hours is similar to those with persisting symptoms (see <ce:cross-ref id="crf0210" refid="b0030">Box 26.3</ce:cross-ref>). The term ‘minor stroke’ is sometimes used to refer to symptoms lasting over 24 hours but not causing significant disability.</ce:para></ce:list-item><ce:list-item id="u0470"><ce:label>•</ce:label><ce:para id="p0705"><ce:italic>Progressing stroke (or stroke in evolution)</ce:italic> describes a stroke in which the focal neurological deficit worsens after the patient first presents. Such worsening may be due to increasing volume of infarction, haemorrhagic transformation or increasing cerebral oedema.</ce:para></ce:list-item><ce:list-item id="u0475"><ce:label>•</ce:label><ce:para id="p0710"><ce:italic>Completed stroke</ce:italic> describes a stroke in which the focal deficit persists and is not progressing.</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p0715">When assessing a patient within hours of symptom onset, it is not possible to distinguish stroke from TIA unless symptoms have already resolved. In clinical practice, it is important to distinguish those patients with strokes who have persisting focal neurological symptoms when seen from those whose symptoms have already resolved.</ce:para></ce:section><ce:section id="s0185"><ce:section-title id="st0180">Investigations</ce:section-title><ce:para id="p0720">Investigation of acute stroke aims to confirm the vascular nature of a lesion, distinguish infarction from haemorrhage and identify the underlying vascular disease and risk factors (<ce:cross-ref id="crf0215" refid="b0040">Box 26.5</ce:cross-ref><ce:float-anchor refid="b0040"/>).</ce:para><ce:section id="s0190"><ce:section-title id="st0185">Risk factor analysis</ce:section-title><ce:para id="p0730">Initial investigation includes a range of simple blood tests to detect common vascular risk factors and markers of rarer causes, along with an ECG and brain imaging. Where there is uncertainty about the nature of the stroke, further investigations are indicated. This especially applies to younger patients, who are less likely to have atherosclerotic disease (<ce:cross-ref id="crf0220" refid="b0045">Box 26.6</ce:cross-ref><ce:float-anchor refid="b0045"/>).</ce:para></ce:section><ce:section id="s0195"><ce:section-title id="st0190">Neuroimaging</ce:section-title><ce:para id="p0740">Brain imaging with either CT or MRI should be performed in all patients with acute stroke. Exceptions are where results would not influence management, such as in the advanced stage of a terminal illness. CT remains the most practical and widely available method of imaging the brain. It will usually exclude non-stroke lesions, including subdural haematomas and brain tumours, and will demonstrate intracerebral haemorrhage within minutes of stroke onset (see <ce:cross-ref id="crf0225" refid="f0060">Fig. 26.9</ce:cross-ref>). However, especially within the first few hours after symptom onset, CT changes in cerebral infarction may be completely absent or only very subtle. Changes often develop over time (see <ce:cross-ref id="crf0230" refid="f0080">Fig. 26.13</ce:cross-ref>) but small cerebral infarcts may never show up on CT scans. For some purposes, a CT scan performed within 24 hours is adequate but there are certain circumstances in which an immediate CT scan is essential (<ce:cross-ref id="crf0235" refid="b0050">Box 26.7</ce:cross-ref><ce:float-anchor refid="b0050"/>). Even in the absence of changes suggesting infarction, abnormal perfusion of brain tissue can be imaged with CT after injection of contrast media (i.e. CT perfusion scanning). This can be useful in guiding immediate treatment of ischaemic stroke.</ce:para><ce:para id="p0770">MRI is not as widely available as CT and scanning times are longer. However, MRI diffusion weighted imaging (DWI) can detect ischaemia earlier than CT, and other MRI sequences can also be used to demonstrate abnormal perfusion (see <ce:cross-ref id="crf0240" refid="f0035">Fig. 26.4</ce:cross-ref>). MRI is more sensitive than CT in detecting strokes affecting the brainstem and cerebellum, and, unlike CT, can reliably distinguish haemorrhagic from ischaemic stroke even several weeks after the onset. CT and MRI may reveal clues as to the nature of the arterial lesion. For example, there may be a small, deep lacunar infarct indicating small-vessel disease, or a more peripheral infarct suggesting an extracranial source of embolism (see <ce:cross-ref id="crf0245" refid="f0065">Fig. 26.10</ce:cross-ref>). In a haemorrhagic lesion, the location might indicate the presence of an underlying vascular malformation, saccular aneurysm or amyloid angiopathy. More recently, CTA is being used to show vessel occlusion suitable for clot retrieval (see later).</ce:para></ce:section><ce:section id="s0200"><ce:section-title id="st0195">Vascular imaging</ce:section-title><ce:para id="p0775">Many ischaemic strokes are caused by atherosclerotic thromboembolic disease of the major extracranial vessels. Detection of extracranial vascular disease can help establish why the patient has had an ischaemic stroke and, in selected patients, may lead on to specific treatments, including carotid endarterectomy to reduce the risk of further stroke (see below). The presence or absence of a carotid bruit is not a reliable indicator of the degree of carotid stenosis. Extracranial arterial disease can be non-invasively identified with duplex ultrasound, MRA or CTA (see <ce:cross-ref id="crf0250" refid="f0040">Fig. 26.5</ce:cross-ref>), or occasionally by intra-arterial contrast radiography as above.</ce:para></ce:section><ce:section id="s0205"><ce:section-title id="st0200">Cardiac investigations</ce:section-title><ce:para id="p0780">Approximately 20% of ischaemic strokes are due to embolism from the heart. The most common causes are atrial fibrillation, prosthetic heart valves, other valvular abnormalities and recent myocardial infarction. These may be identified by clinical examination and ECG, but a transthoracic or transoesophageal echocardiogram is also required to confirm the presence of a clinically apparent cardiac source or to identify an unsuspected source such as endocarditis, atrial myxoma, intracardiac thrombus or patent foramen ovale. Such findings may lead on to specific cardiac treatment.</ce:para></ce:section></ce:section><ce:section id="s0210"><ce:section-title id="st0205">Management</ce:section-title><ce:para id="p0785">Management (<ce:cross-ref id="crf0255" refid="f0070">Fig. 26.11</ce:cross-ref><ce:float-anchor refid="f0070"/>) is aimed at identifying the cause, minimising the volume of brain that is irreversibly damaged, preventing complications (<ce:cross-ref id="crf0260" refid="f0075">Fig. 26.12</ce:cross-ref><ce:float-anchor refid="f0075"/>), reducing the patient's disability and handicap through rehabilitation, and reducing the risk of recurrent stroke or other vascular events. With TIA there is no persisting brain damage and disability, so the priority is to reduce the risk of further vascular events.</ce:para><ce:section id="s0215"><ce:section-title id="st0210">Supportive care</ce:section-title><ce:para id="p0790">Rapid admission of patients to a specialised stroke unit facilitates coordinated care from a specialised multidisciplinary team, and has been shown to reduce both mortality and residual disability amongst survivors. For every 1000 patients managed in a stroke unit, an extra 50 will avoid death or long-term disability, compared to those managed in general wards. Consideration of a patient's rehabilitation needs should commence at the same time as acute medical management. Dysphagia is common and can be detected by an early bedside test of swallowing. This allows hydration, feeding and medication to be given safely, if necessary by nasogastric tube or intravenously. In the acute phase, a checklist may be useful (<ce:cross-ref id="crf0265" refid="b0055">Box 26.8</ce:cross-ref><ce:float-anchor refid="b0055"/>) to ensure that all the factors that might influence outcome have been addressed. In recent years, many services have developed hyperacute stroke units (HASUs) to ensure that patients are given immediate access to these interventions, as well as urgent medical treatments.</ce:para><ce:para id="p0955">The patient's neurological deficits may worsen during the first few hours or days after their onset. This may be due to extension of the area of infarction, haemorrhagic transformation of an infarction, or the development of oedema with consequent mass effect. It is important to distinguish these patients from those who are deteriorating as a result of complications such as hypoxia, sepsis, epileptic seizures or metabolic abnormalities that may be reversed more easily. Patients with cerebellar haematomas or infarcts with mass effect may develop obstructive hydrocephalus and some will benefit from insertion of a ventricular drain and/or decompressive surgery (see <ce:cross-ref id="crf0270" refid="f0070">Fig. 26.11</ce:cross-ref>). Some patients with large haematomas or infarction with massive oedema in the cerebral hemispheres may benefit from anti-oedema agents, such as mannitol or artificial ventilation. Surgical decompression to reduce intracranial pressure should be considered in appropriate patients.</ce:para></ce:section><ce:section id="s0280"><ce:section-title id="st0275">Reperfusion (thrombolysis and thrombectomy)</ce:section-title><ce:para id="p0960">Rapid reperfusion in ischaemic stroke can reduce the extent of brain damage. Intravenous thrombolysis with recombinant tissue plasminogen activator (rt-PA) increases the risk of haemorrhagic transformation of the cerebral infarct with potentially fatal results. The main contraindications are bleeding risk (recent haemorrhage, anticoagulant therapy) and delay to treatment; the earlier treatment is given, the greater the benefit. However, if given within 4.5 hours of symptom onset to carefully selected patients, the haemorrhagic risk is offset by an improved overall outcome. Recently mechanical clot retrieval (thrombectomy) in patients with a large-vessel occlusion can greatly improve the chances of avoiding disability (see <ce:cross-ref id="crf0275" refid="f0070">Fig. 26.11</ce:cross-ref>).</ce:para></ce:section><ce:section id="s0285"><ce:section-title id="st0280">Aspirin</ce:section-title><ce:para id="p0965">In the absence of contraindications, aspirin (300 mg daily) should be started immediately after an ischaemic stroke unless rt-PA has been given, in which case it should be withheld for at least 24 hours. Aspirin reduces the risk of early recurrence and has a small but clinically worthwhile effect on long-term outcome (see <ce:cross-ref id="crf0280" refid="f0070">Fig. 26.11</ce:cross-ref>); it may be given by rectal suppository or by nasogastric tube in dysphagic patients.</ce:para></ce:section><ce:section id="s0290"><ce:section-title id="st0285">Heparin</ce:section-title><ce:para id="p0970">Anticoagulation with heparin has been widely used to treat acute ischaemic stroke in the past. While it reduces the risk of early ischaemic recurrence and venous thromboembolism, it increases the risk of both intracranial and extracranial haemorrhage. Furthermore, routine use of heparin does not result in better long-term outcomes, and therefore it should not be used in the routine management of acute stroke. It is unclear whether heparin might provide benefit in selected patients, such as those with recent myocardial infarction, arterial dissection or progressing strokes. Intracranial haemorrhage must be excluded on brain imaging before considering anticoagulation.</ce:para></ce:section><ce:section id="s0295"><ce:section-title id="st0290">Coagulation abnormalities</ce:section-title><ce:para id="p0975">In those with intracerebral haemorrhage, coagulation abnormalities should be reversed as quickly as possible to reduce the likelihood of the haematoma enlarging. This most commonly arises in those on warfarin therapy. There is no evidence that clotting factors are useful in the absence of a clotting defect.<ce:display><ce:textbox id="b0060" role="alt2"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0120" locator="icon02-9780702070280" xlink:href="pii:B9780702070280000263/icon02-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0250" role="short">Image 13</ce:alt-text></ce:inline-figure>26.9</ce:label><ce:alt-text id="atte0255" role="short">26.9</ce:alt-text><ce:textbox-head><ce:title id="tit0065">Anticoagulation in old age</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p0980"><ce:list id="ulist0215"><ce:list-item id="u0600"><ce:label>•</ce:label><ce:para id="p0985"><ce:bold>Increased risk</ce:bold>: older age and previous stroke increase the risk of stroke in the presence of atrial fibrillation, and bleeding risk with anticoagulation.</ce:para></ce:list-item><ce:list-item id="u0605"><ce:label>•</ce:label><ce:para id="p0990"><ce:bold>Falls risk</ce:bold>: elderly patients are more prone to falls, including head injuries, which increase bleeding risk.</ce:para></ce:list-item><ce:list-item id="u0610"><ce:label>•</ce:label><ce:para id="p0995"><ce:bold>Monitoring of therapy</ce:bold>: fine adjustments to daily dose of warfarin may be more difficult, as may monitoring of therapy.</ce:para></ce:list-item><ce:list-item id="u0615"><ce:label>•</ce:label><ce:para id="p1000"><ce:bold>Impact of comorbidities</ce:bold>: the presence of conditions such as chronic renal impairment, diabetes or heart failure may affect the risk:benefit ratio, and decisions to use anticoagulation must be weighed carefully. Decision aids have been developed to assist (see ‘<ce:cross-ref id="crf0285" refid="st0360">Further information</ce:cross-ref>’).</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox></ce:display></ce:para></ce:section><ce:section id="s0300"><ce:section-title id="st0295">Management of risk factors</ce:section-title><ce:para id="p1005">The approaches used are summarised in <ce:cross-ref id="crf0290" refid="f0080">Figure 26.13</ce:cross-ref><ce:float-anchor refid="f0080"/>. The average risk of a further stroke is 5–10% within the first week of a stroke or TIA, perhaps 15% in the first year and 5% per year thereafter. The risks are not substantially different for intracerebral haemorrhage. The potential gain from good secondary prevention can be expressed as the number needed to treat (NNT) to avoid a recurrent stroke. Patients with ischaemic events should be put on long-term antiplatelet drugs (NNT 100) and statins (NNT 60) to lower cholesterol. For patients in atrial fibrillation, the risk can be reduced substantially (NNT 15) by using oral anticoagulation with warfarin to achieve an international normalised ratio (INR) of 2–3. The newer direct oral anticoagulants (such as dabigatran, rivaroxaban and apixaban) are now widely used, offering improved safety and effectiveness at increased drug cost. The risk of recurrence after both ischaemic and haemorrhagic strokes can be reduced by blood pressure reduction, even for those with relatively normal blood pressures (NNT 50).</ce:para></ce:section><ce:section id="s0305"><ce:section-title id="st0300">Carotid endarterectomy and angioplasty</ce:section-title><ce:para id="p1010">A small proportion of patients with a carotid territory ischaemic stroke or TIA will have more than 50% stenosis of the carotid artery on the side of the brain lesion. Such patients have a greater than average risk of stroke recurrence. For those without major residual disability, removal of the stenosis has been shown to reduce the overall risk of recurrence (NNT 15), although the operation itself carries about a 5% risk of stroke. Surgery is most effective in patients with more severe stenoses (70–99%) and when it is performed within the first couple of weeks after the TIA or ischaemic stroke. Carotid angioplasty and stenting are technically feasible but have not been shown to be as effective as endarterectomy for the majority of eligible patients. Endarterectomy of asymptomatic carotid stenosis has been shown to reduce the subsequent risk of stroke but the small absolute benefit does not justify its routine use.</ce:para></ce:section><ce:section id="s0310"><ce:section-title id="st0305">Unusual causes</ce:section-title><ce:para id="p1015">A minority of strokes are caused by arterial dissection of the carotid (carotid dissection) or vertebral artery (vertebral artery dissection). The presenting history often includes minor injury and face or neck pain. After confirmation on angiography (MRA or CTA), treatment is with either antiplatelet drugs or anticoagulation. Reversible vasoconstriction syndromes require good physiological control (particularly blood pressure).</ce:para></ce:section></ce:section></ce:section><ce:section id="s0315"><ce:section-title id="st0310">Subarachnoid haemorrhage</ce:section-title><ce:para id="p1020">Subarachnoid haemorrhage (SAH) is less common than ischaemic stroke or intracerebral haemorrhage (see <ce:cross-ref id="crf0295" refid="f0020">Fig. 26.1</ce:cross-ref>) and affects about 6/100 000 of the population. Women are affected more commonly than men and the condition usually presents before the age of 65. The immediate mortality of aneurysmal SAH is about 30%; survivors have a recurrence (or rebleed) rate of about 40% in the first 4 weeks and 3% annually thereafter.</ce:para><ce:para id="p1025">Some 85% of cases of SAH are caused by saccular or ‘berry’ aneurysms arising from the bifurcation of cerebral arteries (see <ce:cross-ref id="crf0300" refid="f0025">Fig. 26.2</ce:cross-ref>), particularly in the region of the circle of Willis. The most common sites are in the anterior communicating artery (30%), posterior communicating artery (25%) or middle cerebral artery (20%). There is an increased risk in first-degree relatives of those with saccular aneurysms, and in patients with polycystic kidney disease (<ce:intra-ref id="ii0165" xlink:href="pii:B978-0-7020-7028-0.00015-9#p1755">p. 405</ce:intra-ref>) and congenital connective tissue defects such as Ehlers–Danlos syndrome (<ce:intra-ref id="ii0170" xlink:href="pii:B978-0-7020-7028-0.00023-8#p5845">p. 970</ce:intra-ref>). In about 10% of cases, SAHs are non-aneurysmal haemorrhages (so-called peri-mesencephalic haemorrhages), which have a very characteristic appearance on CT and a benign outcome in terms of mortality and recurrence. Around 5% of SAHs are due to arteriovenous malformations and vertebral artery dissection.</ce:para><ce:section id="s0320"><ce:section-title id="st0315">Clinical features</ce:section-title><ce:para id="p1030">SAH typically presents with a sudden, severe, ‘thunderclap’ headache (often occipital), which lasts for hours or even days, often accompanied by vomiting, raised blood pressure and neck stiffness or pain. It commonly occurs on physical exertion, straining and sexual excitement. There may be loss of consciousness at the onset, so SAH should be considered if a patient is found comatose. About 1 patient in 8 with a sudden severe headache has SAH and, in view of this, all who present in this way require investigation to exclude it (<ce:cross-ref id="crf0305" refid="f0085">Fig. 26.14</ce:cross-ref><ce:float-anchor refid="f0085"/>).</ce:para><ce:para id="p1035">On examination, the patient is usually distressed and irritable, with photophobia. There may be neck stiffness due to subarachnoid blood but this may take some hours to develop. Focal hemisphere signs, such as hemiparesis or aphasia, may be present at onset if there is an associated intracerebral haematoma. A third nerve palsy may be present due to local pressure from an aneurysm of the posterior communicating artery, but this is rare. Fundoscopy may reveal a subhyaloid haemorrhage, which represents blood tracking along the subarachnoid space around the optic nerve.</ce:para></ce:section><ce:section id="s0325"><ce:section-title id="st0320">Investigations</ce:section-title><ce:para id="p1040">CT brain scanning and lumbar puncture are required. The diagnosis of SAH can be made by CT but a negative result does not completely exclude it, since small amounts of blood in the subarachnoid space cannot be detected by CT (see <ce:cross-ref id="crf0310" refid="f0085">Fig. 26.14</ce:cross-ref>). Lumbar puncture should be performed 12 hours after symptom onset if possible, to allow detection of xanthochromia (<ce:intra-ref id="ii0175" xlink:href="pii:B978-0-7020-7028-0.00025-1#s0185">p. 1077</ce:intra-ref>). If either of these tests is positive, cerebral angiography (see <ce:cross-ref id="crf0315" refid="f0040">Fig. 26.5</ce:cross-ref>) is required to determine the optimal approach to prevent recurrent bleeding.</ce:para></ce:section><ce:section id="s0330"><ce:section-title id="st0325">Management</ce:section-title><ce:para id="p1045">Nimodipine (30–60 mg IV for 5–14 days, followed by 360 mg orally for a further 7 days) is usually given to prevent delayed ischaemia in the acute phase. Insertion of platinum coils into an aneurysm (via an endovascular procedure) or surgical clipping of the aneurysm neck reduces the risk of both early and late recurrence. Coiling is associated with fewer perioperative complications and better outcomes than surgery; where feasible, it is now the procedure of first choice. Arteriovenous malformations can be managed either by surgical removal, by ligation of the blood vessels that feed or drain the lesion, or by injection of material to occlude the fistula or draining veins. Treatment may also be needed for complications of SAH, which include obstructive hydrocephalus (that may require drainage via a shunt), delayed cerebral ischaemia due to vasospasm (which may be treated with vasodilators), hyponatraemia (best managed by fluid restriction) and systemic complications associated with immobility, such as chest infection and venous thrombosis.</ce:para></ce:section></ce:section><ce:section id="s0335"><ce:section-title id="st0330">Cerebral venous disease</ce:section-title><ce:para id="p1050">Thrombosis of the cerebral veins and venous sinuses (cerebral venous thrombosis) is much less common than arterial thrombosis. However, it has been recognised with increasing frequency in recent years, as access to non-invasive imaging of the venous sinuses using MR venography has increased. The main causes are listed in <ce:cross-ref id="crf0320" refid="b0065">Box 26.10</ce:cross-ref><ce:float-anchor refid="b0065"/>.</ce:para><ce:section id="s0340"><ce:section-title id="st0335">Clinical features</ce:section-title><ce:para id="p1120">Cerebral venous sinus thrombosis usually presents with symptoms of raised intracranial pressure, seizures and focal neurological symptoms. The clinical features vary according to the sinus involved (<ce:cross-ref id="crf0325" refid="b0070">Box 26.11</ce:cross-ref><ce:float-anchor refid="b0070"/> and see <ce:cross-ref id="crf0330" refid="f0030">Fig. 26.3</ce:cross-ref>). Cortical vein thrombosis presents with focal cortical deficits such as aphasia and hemiparesis (depending on the area affected), and epilepsy (focal or generalised). The deficit can increase if spreading thrombophlebitis occurs.</ce:para></ce:section><ce:section id="s0360"><ce:section-title id="st0355">Investigations and management</ce:section-title><ce:para id="p1175">MR venography demonstrates a filling defect in the affected vessel. Anticoagulation, initially with heparin followed by warfarin, is beneficial, even in the presence of venous haemorrhage. In selected patients, endovascular thrombolysis has been advocated. Management of underlying causes and complications, such as persistently raised intracranial pressure, is important.</ce:para><ce:para id="p1185">About 10% of cerebral venous sinus thrombosis, particularly cavernous sinus thrombosis, is associated with infection (most commonly <ce:italic>Staphylococcus aureus</ce:italic>), needing antibiotic treatment. Otherwise, the treatment of choice is anticoagulation.</ce:para></ce:section></ce:section></ce:sections><ce:further-reading id="fr0010"><ce:section-title id="st0360">Further information</ce:section-title><ce:further-reading-sec id="fs0010"><ce:section-title id="st0365">Websites</ce:section-title><ce:bib-reference id="bib3"><ce:label>,</ce:label><sb:reference id="sr0015"><sb:host><sb:e-host><ce:inter-ref id="iw0015" xlink:href="http://eso-stroke.org">eso-stroke.org</ce:inter-ref></sb:e-host></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib4"><ce:label>,</ce:label><ce:note><ce:simple-para id="sp0155"><ce:italic>European Stroke Organisation guidelines.</ce:italic></ce:simple-para></ce:note></ce:bib-reference><ce:bib-reference id="bib5"><ce:label>,</ce:label><sb:reference id="sr0020"><sb:host><sb:e-host><ce:inter-ref id="iw0020" xlink:href="http://nhs.uk/actfast">nhs.uk/actfast</ce:inter-ref></sb:e-host></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib6"><ce:label>,</ce:label><ce:note><ce:simple-para id="sp0160"><ce:italic>FAST (face, arms, speech, time) campaign to raise public awareness of the emergency nature of stroke.</ce:italic></ce:simple-para></ce:note></ce:bib-reference><ce:bib-reference id="bib7"><ce:label>,</ce:label><sb:reference id="sr0025"><sb:host><sb:e-host><ce:inter-ref id="iw0025" xlink:href="http://nice.org.uk/guidance">nice.org.uk/guidance</ce:inter-ref></sb:e-host></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib8"><ce:label>,</ce:label><ce:note><ce:simple-para id="sp0165"><ce:italic>National Institute for Health and Care Excellence CG180 ‘Tools and resources’ includes a patient decision aid – Atrial fibrillation: medicines to help reduce your risk of a stroke – what are the options?</ce:italic></ce:simple-para></ce:note></ce:bib-reference><ce:bib-reference id="bib10"><ce:label>,</ce:label><sb:reference id="sr0030"><sb:host><sb:e-host><ce:inter-ref id="iw0030" xlink:href="http://rcplondon.ac.uk/resources/stroke-guidelines">rcplondon.ac.uk/resources/stroke-guidelines</ce:inter-ref></sb:e-host></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib11"><ce:label>,</ce:label><ce:note><ce:simple-para id="sp0175"><ce:italic>Royal College of Physicians of London clinical guideline.</ce:italic></ce:simple-para></ce:note></ce:bib-reference><ce:bib-reference id="bib1"><ce:label>,</ce:label><sb:reference id="sr0010"><sb:host><sb:e-host><ce:inter-ref id="iw0010" xlink:href="http://stroke.cochrane.org">stroke.cochrane.org</ce:inter-ref></sb:e-host></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib2"><ce:label>,</ce:label><ce:note><ce:simple-para id="sp0150"><ce:italic>Systematic reviews of stroke treatments.</ce:italic></ce:simple-para></ce:note></ce:bib-reference><ce:bib-reference id="bib12"><ce:label>,</ce:label><sb:reference id="sr0035"><sb:host><sb:e-host><ce:inter-ref id="iw0035" xlink:href="http://stroketraining.org">stroketraining.org</ce:inter-ref></sb:e-host></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib13"><ce:label>,</ce:label><ce:note><ce:simple-para id="sp0180"><ce:italic>Stroke Training and Awareness Resources.</ce:italic></ce:simple-para></ce:note></ce:bib-reference></ce:further-reading-sec></ce:further-reading></chapter>